# Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms

Study · id `cardio:ct-nct03728985` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03728985](<https://clinicaltrials.gov/study/NCT03728985>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT03728985

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 102 participants.

## Technical summary

Registry record NCT03728985. Non-randomized; no masking; primary purpose treatment. Start 2019-06-17 (actual); primary completion 2023-01-04 (actual). Results posted on 2024-08-05.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 102 participants (enrolled count; ClinicalTrials.gov record NCT03728985, source copy `cardio:ctgov-nct03728985-2026-09-02`, retrieved 2026-11-18)
- Started: 2019-06-17 (actual) (ClinicalTrials.gov record NCT03728985, source copy `cardio:ctgov-nct03728985-2026-09-02`, retrieved 2026-11-18)
- Primary completion: 2023-01-04 (actual) (ClinicalTrials.gov record NCT03728985, source copy `cardio:ctgov-nct03728985-2026-09-02`, retrieved 2026-11-18)
- Completion: 2030-01 (anticipated) (ClinicalTrials.gov record NCT03728985, source copy `cardio:ctgov-nct03728985-2026-09-02`, retrieved 2026-11-18)
- Results first posted: 2024-08-05 (ClinicalTrials.gov record NCT03728985, source copy `cardio:ctgov-nct03728985-2026-09-02`, retrieved 2026-11-18)
- Countries: United States; United Kingdom (ClinicalTrials.gov record NCT03728985, source copy `cardio:ctgov-nct03728985-2026-09-02`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03728985-2026-09-02`, retrieved 2026-11-18)

## The registry's words

- Brief title: Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms
- Acronym: TAMBE
- Condition: Thoracoabdominal Aortic Aneurysm
- Intervention (Device): GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis
- Lead sponsor: W.L.Gore & Associates
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic aneurysm (`cardio:aortic-aneurysm`)
- Registry lists this organization as the lead sponsor: W.L.Gore & Associates (`cardio:org-w-l-gore-associates`)

## Provenance

Content hash: 289268dbf42c3ec1cf86c48e960c4a0da3e38143e2b9042498985ab74ceb6547
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
